Masataka Kuwana

Dec 23, 2024 | acrjournals.onlinelibrary.wiley.com | Elizabeth R Volkmann |Holly Wilhalme |Donald Tashkin |Jonathan Goldin |Alana Haussmann |Masataka Kuwana | +2 more

Supporting Information Filename Description acr25485-sup-0001-Disclosureform.pdfPDF document, 671.5 KB Disclosure Form acr25485-sup-0002-supinfo.docxWord 2007 document , 331.1 KB Supporting Information

Dec 1, 2024 | jrheum.org | Masataka Kuwana |Naoko Wakasugi |Tetsuji Hashida |Satoshi Uno

To the Editor: In 2013, tacrolimus was approved in Japan for the treatment of interstitial lung disease (ILD) in patients with polymyositis (PM)/dermatomyositis (DM).1 Subsequently, Kuwana et al2 reported the 2-year interim prospective results of a postmarketing surveillance study, which found that tacrolimus-containing immunosuppressive regimens were well tolerated in patients with PM/DM-associated ILD.2 As the maximum 3-year surveillance period has been completed, we now report the safety...

Feb 14, 2023 | tandfonline.com | Masataka Kuwana

AbstractBackground Interstitial lung disease (ILD) is a common complication of connective tissue diseases (CTD), but there are few clinical trials to guide disease management. We aimed to develop expert consensus statements and an algorithm for CTD-ILD management. Research design and methods Based on a targeted literature review, we developed 109 statements on managing CTD-ILD across six domains.